Skip to Content
Merck
  • Dehydrozingerone, chalcone, and isoeugenol analogues as in vitro anticancer agents.

Dehydrozingerone, chalcone, and isoeugenol analogues as in vitro anticancer agents.

Journal of natural products (2006-10-28)
Jin Tatsuzaki, Kenneth F Bastow, Kyoko Nakagawa-Goto, Seiko Nakamura, Hideji Itokawa, Kuo-Hsiung Lee
ABSTRACT

Twenty-eight compounds related to dehydrozingerone (1), isoeugenol (3), and 2-hydroxychalcone (4) were synthesized and evaluated in vitro against human tumor cell replication. Except for isoeugenol analogues 27-35, most compounds exhibited moderate or strong cytotoxic activity against KB, KB-VCR (a multidrug-resistant derivative), and A549 cell lines. In particular, chalcone 15 showed significant cytotoxic activity against the A549 cell line with an IC50 value of 0.6 microg/mL. Furthermore, dehydrozingerone analogue 11 and chalcones 16 and 17 showed significant and similar cytotoxic activity against both KB (IC50 values of 2.0, 1.0, and 2.0 microg/mL, respectively) and KB-VCR (IC50 values of 1.9, 1.0, and 2.0 microg/mL, respectively) cells, suggesting that they are not substrates for the P-glycoprotein drug efflux pump.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Benzylideneacetone, ≥98%, FG
Sigma-Aldrich
4-Phenyl-3-buten-2-one, 99%
Sigma-Aldrich
Methyl isoeugenol, ≥98%, FG
Sigma-Aldrich
trans-4-Phenyl-3-buten-2-one, ≥99%